Can Biogen Catch up to Merck in Alzheimer's Race?

A collaboration pact with Eisai puts Biogen Idec right in the middle of a race to develop the first BACE inhibitor.

Mar 12, 2014 at 2:30PM

Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely clear, and the exact cause of their destruction is even cloudier. Flush with cash from the successful launch of Tecfidera, Biogen Idec (NASDAQ:BIIB) is taking a shot at one of the largest unmet needs in medicine.

There are no drugs that can effectively prevent the progression of AD. Attempts to develop the first have been met with one expensive failure after another. Partners Pfizer and Johnson & Johnson lost big when bapineuzumab failed a Phase 3 trial with mild-to-moderate patients. Few were surprised when Eli Lilly (NYSE:LLY) announced a similar Phase 3 failure with solanezumab.

Undaunted, Biogen Idec has recently upped its commitment in the AD field. The neuroscience specialists inked a collaboration pact with Japan's Eisai over the development of several compounds. The most notable is E2609, an oral BACE inhibitor. After the failure of high-profile antibodies like bapineuzumab and solanezumab, these small-molecule drugs are getting all the attention in the race to treat AD.

Leading the race
Despite the trail of wasted R&D resources AD has left in its wake, there is no shortage of companies making attempts. Leading the charge is Merck (NYSE:MRK) with its BACE inhibitor MK-8931.

The candidate is in a Phase 2-3 study with mild to moderate AD patients. Late last year, an independent data monitoring committee finished a planned interim safety analysis of the trial. Merck and its competitors breathed a collective sigh of relief when the committee gave the green light. The trial can now continue recruiting patients without changing its design.

Anxiety cured
Any safety analysis is stressful in mid to late-stage development, but Merck's was more of a nail-biter than most. Last June, Eli Lilly voluntarily terminated a mid-stage study with its BACE inhibitor, LY2886721, due to "abnormal liver biochemical tests," although the same press release indicated that Lilly "believes that the abnormal liver biochemical tests...are not related to the BACE mechanism." Last fall, Roche quietly terminated development of a BACE inhibitor it had in early stage clinical trials as well. Unlike Lilly's BACE dismissal, Roche cut its program silently without giving any clues as to why. Hot on the heels of Lilly's announcement, some probably feared that Roche's withdrawal, and in turn all BACE inhibitors, might cause liver damage.

Now that Merck's BACE inhibitor has shed safety concerns, confidence in this promising class of AD therapies should get a nice boost. The race to win the first approval should heat up as well. Luckily Biogen Idec won't be starting from zero. Eisai's, and now Biogen's, E2609 was "undergoing preparations to enter Phase 2 clinical trials" when the companies announced their collaboration.

Clearing a path
Also boosting confidence for this therapy class, and AD in general, is a new attitude from regulators. Previously the FDA insisted on measurement of a patient's ability to function. If patients without AD symptoms are treated, however, changes in their functional ability might be nearly impossible to measure. Just over a year ago, the agency issued a new draft guidance for the industry. It has gone a long way to define a path to approval for drugs that slow the progression of AD before patients show any symptoms of the disease. The pathway isn't so well defined yet, but the agency is clearly willing to accept new approaches for measuring efficacy. 

What to look for
Personally, I wouldn't be surprised if Merck's late-stage trial with MK-8931 doesn't result in an approval. I don't think there's anything that's anything inherently wrong with the drug, but I worry that the patients with "moderate" AD symptoms may not improve, and that result would mar the trial's efficacy data. That would put Biogen not so far behind with E2609, which is now entering a Phase 2 trial.

Keep your eyes open for a long-term pivotal trial involving subjects that are at risk but not yet displaying AD symptoms. The first to enter such a trial, with endpoints developed according to FDA guidance, may win the BACE race.

Should you own Biogen forever?
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "
3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers